Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study
Φόρτωση...
Ημερομηνία
Συγγραφείς
Temekonidis, T. I.
Alamanos, Y.
Nikas, S. N.
Bougias, D. V.
Georgiadis, A. N.
Voulgari, P. V.
Drosos, A. A.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Ann Rheum Dis
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVE: To evaluate the efficacy and safety of long term infliximab therapy in patients with severe refractory ankylosing spondylitis (AS). PATIENTS AND METHODS: Twenty five patients (24 male, 1 female; mean (SD) age 36.0 (10.5); disease duration 13.8 (8.5) years) with AS fulfilling the modified New York criteria for AS were investigated. Twenty two (88%) patients were HLA-B27 positive. All patients had active axial disease (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >/=30/100) and C reactive protein (CRP) >/=10 mg/l, despite adequate treatment. Intravenous infliximab (5 mg/kg) was given at weeks 0, 2, 6, and every eight weeks thereafter for 12 months. The primary end point was the reduction of the patient's global assessment of pain (GAP) by >20% on a 100 mm visual analogue scale. RESULTS: GAP was reduced by >20% in 23 (92%) patients, by 50% in 21 (84%) patients, and by 70% in 13 (52%). The change in BASDAI and CRP from baseline was statistically significant. The treatment was well tolerated with minimal side effects. One patient dropped out owing to inefficacy and one stopped treatment owing to an allergic reaction. CONCLUSION: This longer length study confirms the efficacy of infliximab and the good safety profile in patients with AS.
Περιγραφή
Λέξεις-κλειδιά
Adult, Antibodies, Monoclonal/*therapeutic use, Antirheumatic Agents/*therapeutic use, Chronic Disease, Drug Evaluation, Drug Resistance, Female, Humans, Infusions, Intravenous, Male, Pain/prevention & control, Spondylitis, Ankylosing/*drug therapy, Treatment Outcome
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/14644863
http://ard.bmj.com/content/62/12/1218.full.pdf
http://ard.bmj.com/content/62/12/1218.full.pdf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής